We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Advanced Medical Solutions Group Plc | LSE:AMS | London | Ordinary Share | GB0004536594 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.80 | -0.43% | 185.80 | 185.60 | 187.00 | 188.80 | 185.20 | 187.40 | 272,263 | 16:35:08 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Plastics,resins,elastomers | 126.21M | 15.89M | 0.0732 | 25.44 | 404.45M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/5/2016 12:58 | Someone's keen... 325,000 vol trade. | jangaman | |
26/5/2016 14:16 | Another good day (... towards USA T/O?) | small crow | |
25/5/2016 16:46 | looks like Octupus pushing it for performance | norbus | |
25/5/2016 15:50 | New share price high today one wonders how high they will go? | dealit | |
05/4/2016 08:11 | I am puzzled as to the reason that the PMA route is being chosen to market LiquiBand ®Fix 8™ in the USA as it will take around 3 years Why are they not taking the 510K route which will only take around 6 months ? Does anyone know why ? From the results Regulatory and quality assurance With the regulatory framework becoming increasingly complex, we have continued to invest in both Regulatory and Quality functions and systems to ensure that we are able to support our partners with winning approvals in new markets as well as obtaining approval for our own products. We have started work on scoping the process to gain approval to market LiquiBand ®Fix 8™ in the US which will involve a full Pre Market Approval (PMA) and is likely to take at least three years. | buywell3 | |
16/3/2016 08:16 | £4m of the £5.6m growth came from US : Double edged sword ? | norbus | |
16/3/2016 07:34 | New web site very useful: | mirandaj | |
16/3/2016 07:22 | Good solid results, love the growth in the USA. | dealit | |
14/3/2016 18:22 | Lets hope the results are positive Norbus. | dealit | |
14/3/2016 14:54 | always bullish across accounts | norbus | |
04/3/2016 16:14 | Mirandaj, AMS IMHO have turned into a rock solid share to own. Great product range as you point out award winning + dividend. I have held for many years, I cannot see why they have not been snapped up as of yet, maybe share price getting to expensive now. | dealit | |
04/3/2016 13:43 | Pre Close statement: Product of the year award for their LiquiBand® Fix8™ Hernia Mesh Fixation device. | mirandaj | |
29/2/2016 17:31 | Not long to wait for results now if as last year, lets hope things are ok and positive. | dealit | |
12/2/2016 12:49 | It certainly is - I've increased a couple of times:-) apad | apad | |
12/2/2016 12:42 | One wonders if the share price pull back is temping to a predatory attack on AMS? IMHO | dealit | |
06/1/2016 12:03 | Very strongly held, From the AMS website. Blackrock 7.82% AXA Framlington Investment Managers 7.40% Octopus Investors 6.95% Investec Wealth & Investment Management 5.26% Schroder Investment Management 4.67% Aviva Investors 4.59% Artemis Investment Management 3.83% Invesco Perpetual 3.47% Hargreave Hale, Stockbrokers (ND) 3.35% Charles Stanley, Stockbrokers 3.24% | whitebicycle | |
06/1/2016 11:04 | Yes I agree IMHO would seem MM`s holding price back. | dealit | |
06/1/2016 10:21 | Anyone else get that feeling a big order is being filled? | small crow | |
19/12/2015 17:38 | It would make a good stocking filler for J&J | norbus | |
19/12/2015 13:45 | USA interest rate rise dollar stronger could be the trigger for a USA based pharma to make a move on AMS IMHO. | dealit | |
18/12/2015 20:37 | WhiteBicycle It was just your timing that was wrong I suspect.... | small crow | |
18/12/2015 19:54 | Sorry wrong share, but well pleased with AMS. | whitebicycle |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions